China: Patent Law Revisions In China

Last Updated: 8 May 2009
Article by Lisa Haile

New amendments predicted to affect intellectual property protection.

The new year will bring many changes and their associated risks and opportunities. With President-elect Barack Obama leading the U.S. through one of the murkiest financial times in history, many are looking toward China in the year of Yi Chou, or the Ox, as we contemplate alternative funding sources, manufacturing locations, and sites for performing clinical trials.

It appears that China is poised to become one of the new centres of innovation. China intends to soon grant more patents than any other country and expects to entice most of the top pharmaceutical companies to conduct R&D within its borders. It is believed that China's government may show more incentive to enforce patent rights within the country if the local companies in China feel that they have innovative technologies and are, therefore, stakeholders in the growing biotech industry.

China's patent laws were initially created in 1984, long after most other countries worldwide. The patent laws have been revised two times since 1984, first in 1992 and again in 2000. A third proposed revision is expected to be finalized early in 2009 by the PRC State Intellectual Property Office (SIPO). Part of the intent behind the proposed amendments is to provide China with protection that will be both in line with national interests and supportive of domestic innovation.

In the past, investors have been reluctant to put their money in a country where patent protection and enforcement are unpredictable. Even though China has an obligation to protect intellectual property (IP) since joining the World Trade Organization in 2001, efforts toward IP protection have not been evident.

New amendments predicted to affect intellectual property protection. Several foreign business associations, especially from Europe and the USA, have been closely monitoring the drafting process and actively lobbying for specific changes. There have been many concerns, especially over the requirement that an applicant disclose the source of genetic material as part of the patent application process and proposals for substantive requirements not found in Trade Related Aspects of Intellectual Property Rights (TRIPS), an international agreement administered by the World Trade Organization that sets down minimum standards for many forms of IP regulation.

With respect to enforcement, the proposed amendments include raising the penalty for patent infringement from 300% to 400% of illicit profits and increasing the damage payment from 50,000 Yuan to 200,000 Yuan, even if there is no profit from infringement. It is believed that such deterrents will change the perception that China is too lenient with respect to enforcement of IP rights, especially for foreign patentees.

Article 48 of the amendment allows the granting of a compulsory license when a patentee is determined to be abusing his IP rights in order to prevent or restrict competition. In addition, the draft amendment outlines several situations where a compulsory license for a patent may be granted by the SIPO. Articles 49 and 50 allow for the granting of a compulsory license in order to treat or prevent an epidemic in China, or when a developing country needs to import a pharmaceutical product from China for the same purposes. In the USA, a similar provision is called march-in-rights.

What is more disconcerting is the proposal to grant a compulsory license, upon request, for the use of a patented invention if the patent owner, 'without any legitimate reason', has not 'adequately practiced the patented invention for three years after issuance of the patent...'. This section of the compulsory license amendment may be especially prejudicial for the biotechnology industry.

Consider the typical situation where a technology is under development and a patent application is filed in the USA, followed by a Patent Cooperation Treaty (PCT) application, and then later filed in China.

In many instances, the claims that are issued or granted in a patent (the patented invention) are not actually practiced at the time of the patent grant or even within three years of the patent grant. Should companies consider setting up a small clinical trial in China as soon as the Chinese patent is granted? Would that qualify as adequately practicing the claimed invention?

The ambiguity in the language of this proposed amendment, combined with the potential impact of patentees losing rights in China for inventive contributions as determined by the SIPO makes this section particularly disturbing for life sciences companies seeking patent protection in China.

PATENT INFRINGE MENT

Article 74 proposes to add 'parallel importation' as an exception to infringement. This amendment would clearly jeopardise the rights of patent holders in China. For example, if a product patented in China is sold outside of China and then imported back into China by another party, the Chinese patent rights are deemed to be exhausted.

What would prevent individuals or companies from targeting particular Chinese patented products in a troll-like manner, waiting for them to be exported from China, and then immediately importing them back into China with no penalty? Where is the incentive for foreign businesses to patent and manufacture their product in China knowing that exportation of the product would likely lead to future patent exhaustion based on acts of others that are out of their control?

An additional amendment to Article 74 provides an exception to infringement similar to the USA Bolar exception. It would allow the use of a Chinese-patented invention without running the risk of an allegation of infringement, if the otherwise infringing use is shown to be 'related to providing information required to obtain regulatory approval.'

Similar to the situation in the USA, this would also allow a generic drug manufacturer to prepare for product launch once the brand-name drug patent expires. This amendment would certainly make it more attractive for generic drug companies to begin to set up manufacturing facilities in China.

FILING IN CHINA FIRST

The current patent law in China requires Chinese individuals and entities to first file applications in China for inventions made in China. The amendments propose to extend the requirement to non-Chinese individuals and companies or 'any individual or organisation' such that an inventor must file a patent application in China first if 'an invention is made in China'.

The controversial aspect of this amendment is that when a patent application is filed outside of China for any invention made first in China (including improvements of existing inventions) without permission from the Chinese patent administration, a patent application filed later in China based on the same subject matter and/or claiming priority to the foreign filed application, will be denied approval in China.

These proposals are found in amended Articles 4, 20, and 76. This new rule will prevent a foreign parent or partner company from having a choice as to where the patent application is to be filed first, regardless of the citizenship of the inventors.

How will this affect investors or potential partners doing deals in China for research and development? In the USA, having a patent portfolio including at least one if not more filed patent applications in the United States Patent and Trademark Office is sometimes critical to tip the scales toward investment or a pass on an opportunity. Will investors and potential development partners be swayed by the existence of patent applications filed only in China where the patent laws and their application through the SIPO are much less predictable? This lack of clarity and fear of inability to obtain valuable patents in China could greatly affect the desire of companies to do business in the country.

As the laws and court system in China slowly develop and evolve, foreign companies should be diligent in weighing the risks and benefits of doing business in China. A combination of language and cultural differences initially make it more difficult for foreigners, especially since guanxi, which is the basic dynamic of personal and social relationships, ultimately prevails in doing business in China.

This article was original published in Genetic Engineering & Biotechnology News (www.genengnews.com ), January 1 2009 (vol 29, No1).

Phillips Fox has changed its name to DLA Phillips Fox because the firm entered into an exclusive alliance with DLA Piper, one of the largest legal services organisations in the world. We will retain our offices in every major commercial centre in Australia and New Zealand, with no operational change to your relationship with the firm. DLA Phillips Fox can now take your business one step further − by connecting you to a global network of legal experience, talent and knowledge.

This publication is intended as a first point of reference and should not be relied on as a substitute for professional advice. Specialist legal advice should always be sought in relation to any particular circumstances and no liability will be accepted for any losses incurred by those relying solely on this publication.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
 
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions